Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Surgery
Share your love
Iridotomy: Indications, Benefits and Risks
What Is Iridotomy? Iridotomy, often referred to as laser iridotomy, is a surgical procedure aimed at treating certain types of glaucoma and other eye conditions that cause an abnormal increase in intraocular pressure (IOP). It involves creating a tiny hole…
Vitamins for Glaucoma Treatment | OBN
What Is Glaucoma? Glaucoma is a collection of eye disorders that can result in irreversible vision loss by causing damage to the optic nerve, which transmits visual information from the eye to the brain. Glaucoma is often caused by increased…
OMNI Surgical System Greatly Reduces Medication Usage
Sight Sciences released study findings demonstrating that patients with glaucoma who had undergone procedures using their OMNI Surgical System technology had a greater average reduction in the usage of intraocular pressure-lowering medication compared to those who had received only minimally…
Belkin’s Eagle Device FDA Cleared for Laser Trabeculoplasty
Belkin Vision has received FDA 510(k) clearance for its Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser developed for selective laser trabeculoplasty (SLT). The Eagle is positioned by Belkin as the first and only contactless laser for glaucoma, offering…
Keratoprosthesis: An Innovative Surgical Procedure
Keratoprosthesis refers to an innovative surgical procedure designed to restore vision in individuals suffering from severe corneal disease or damage. The term ‘keratoprosthesis’ is derived from the Greek words ‘kerato,’ meaning cornea, and ‘prosthesis,’ meaning artificial addition. The cornea, being…
Carl Zeiss Meditec to Acquire D.O.R.C.
Carl Zeiss Meditec AG announced that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from Eurazeo SE, based in Paris, France. The deal is worth €985 million (nearly…
Sight Sciences Applauds Medicare’s MIGS Decision
Sight Sciences expressed its support for the decision made by five Medicare Administrative Contractors to withdraw their previously announced final local coverage determinations (LCDs) for Micro-Invasive Glaucoma Surgery, originally slated to become effective on January 29, 2024. The five MACs—WPS…
5 Dos and 5 Don’ts After Laser Eye Surgery
Laser eye surgery has become a popular solution for correcting vision problems such as nearsightedness, farsightedness, and astigmatism. While the procedure is known for its high success rate and quick recovery times, proper post-operative care is crucial to achieve optimal…
LEP Biomedical Gains Funding for HyaGuard Platform
LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Innovative Design of HyaGuard…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…